In recent years, the battle against acute myeloid leukemia (AML) has been fraught with challenges, particularly due to the persistent problem of drug resistance. A study published in Cell Death Discovery by Fu, Ng, Tseng, and colleagues in 2026 offers a groundbreaking perspective on overcoming resistance to cabozantinib, a tyrosine kinase inhibitor, in AML models harboring FLT3-ITD mutations. This research delves into the metabolic underpinnings that contribute to therapeutic resistance and suggests innovative strategies to subvert these mechanisms, potentially revolutionizing treatment paradigms.
AML is a devastating hematologic malignancy characterized by the rapid growth of abnormal white blood cells in the bone marrow, interfering with normal hematopoiesis. Among various genetic aberrations driving its aggressiveness, the internal tandem duplication (ITD) mutation in the FLT3 gene is associated with particularly poor prognosis. While targeted therapies, such as FLT3 inhibitors, have improved outcomes, resistance invariably arises, complicating long-term management. Cabozantinib, which inhibits multiple kinases including FLT3, has shown promise but is no exception to resistance development.
The team’s research pivots on the hypothesis that metabolic reprogramming—a hallmark of cancer—plays a critical role in how AML cells escape cabozantinib’s cytotoxicity. Using sophisticated cell models of FLT3-ITD AML, they meticulously charted changes in metabolic pathways as cells acquired drug resistance. By integrating multi-omic analyses including transcriptomics, metabolomics, and proteomics, they painted a comprehensive picture of the metabolic adaptations fueling survival under therapeutic pressure.
One of the most striking findings of the study is the shift in energy metabolism characterized by an enhanced reliance on oxidative phosphorylation (OXPHOS). Whereas sensitive AML cells predominantly utilize glycolysis for their energy demands, resistant cells exhibited a metabolic switch, increasing mitochondrial respiration to meet their bioenergetic needs. This adaptation not only supports survival but also grants cells metabolic flexibility, rendering them less susceptible to cabozantinib’s inhibitory effects on proliferative signaling.
Moreover, the researchers identified a pivotal rewiring of amino acid metabolism, particularly glutamine metabolism, which fuels the tricarboxylic acid (TCA) cycle and maintains redox balance in resistant cells. This metabolic flux supports the synthesis of critical biomolecules and antioxidants, helping cells withstand oxidative stress induced by cabozantinib. Elevated glutaminase activity emerged as a hallmark of resistance, suggesting that targeting glutamine metabolism could sensitize cells to treatment.
Furthermore, lipid metabolism was found to be substantially altered. Resistant AML cells showed increased fatty acid oxidation (FAO), which contributes not only to energy production but also to membrane biosynthesis and signaling molecules crucial for survival signaling pathways. This expansion of FAO creates an alternative metabolic reservoir that maintains cell viability in the face of kinase inhibition.
Building upon these insights, the authors explored therapeutic avenues aimed at reversing resistance by modifying the metabolic landscape. Pharmacologic inhibition of mitochondrial complex I, glutaminase, and fatty acid oxidation enzymes displayed significant synergistic effects when combined with cabozantinib, restoring drug sensitivity and inducing apoptosis in resistant AML cells. These findings point toward a multi-pronged metabolic intervention strategy that could preclude or overcome resistance.
Interestingly, the study also underscores the interplay between oncogenic signaling and metabolic regulation. FLT3-ITD signaling not only drives proliferation but also orchestrates metabolic gene expression programs that enable the metabolic plasticity observed in resistant cells. Interrupting this crosstalk disrupts AML cells’ adaptive capacity, highlighting the interconnectedness of genetic and metabolic vulnerabilities.
Importantly, this research emphasizes the utility of integrating comprehensive metabolic profiling in preclinical models to unveil resistance mechanisms that might otherwise remain obscured in genomics-focused approaches. By unraveling the metabolic dependencies of resistant AML cells, the study sets the stage for personalized metabolic interventions tailored to patients’ evolving tumor biology.
The translational value of these findings is substantial. Given that cabozantinib and metabolic inhibitors are already in clinical use or trials for various cancers, this study lays a practical framework for rapid clinical translation. Combination regimens guided by metabolic biomarkers have the potential to delay or abolish resistance, thereby prolonging remissions and improving survival outcomes for patients with FLT3-ITD AML.
Future research is warranted to evaluate the safety and efficacy of these metabolic combinations in vivo and in clinical trials. Equally important is the development of robust metabolic biomarkers to identify patients at risk of developing resistance and to monitor metabolic shifts during therapy. Such dynamic assessment will enhance the precision of therapeutic interventions and minimize unnecessary toxicities.
Finally, this study redefines our understanding of drug resistance in AML as a multifaceted phenomenon governed not only by genetic mutations but also by adaptive metabolic networks. Therapeutic strategies that incorporate metabolism-centric insights are poised to transform AML treatment and inspire analogous approaches in other malignancies characterized by targeted therapy resistance.
The pioneering work by Fu et al. demonstrates that it is possible to outmaneuver AML cells’ cunning metabolic reprogramming through strategic modulation of their metabolic signatures. This offers a beacon of hope for patients battling resistant AML, underscoring the power of deep mechanistic understanding to unlock new horizons in cancer therapy.
Subject of Research:
Acute myeloid leukemia (AML) with FLT3-ITD mutations and mechanisms of cabozantinib resistance.
Article Title:
Modulating metabolic signatures to mitigate cabozantinib resistance in FLT3-ITD acute myeloid leukemia cell models.
Article References:
Fu, YH., Ng, K.M., Tseng, CY. et al. Modulating metabolic signatures to mitigate cabozantinib resistance in FLT3-ITD acute myeloid leukemia cell models. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-02957-8
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41420-026-02957-8
